The Scientific World Journal

The Scientific World Journal / 2012 / Article

Review Article | Open Access

Volume 2012 |Article ID 940613 | 9 pages |

An Emerging New Paradigm in Opioid Withdrawal: A Critical Role for Glia-Neuron Signaling in the Periaqueductal Gray

Academic Editor: W. Ma
Received21 May 2012
Accepted06 Jun 2012
Published02 Aug 2012


The chronic use of opiates (i.e., narcotics such as the natural derivatives of opium including morphine or codeine) or opioids (i.e., semisynthetic derivatives of opium and other molecules that activate opioid receptors) induces dependence, which is associated with various specific behavioral and somatic signs after their withdrawal or after the administration of an opioid antagonist. Among the brain regions implicated in opiate dependence and withdrawal, the periaqueductal gray area (PAG) appears to be critical in regulating the complex signs and symptoms of opioid withdrawal. Numerous neurochemical mechanisms in the PAG have been identified that may contribute to the opioid withdrawal syndrome. Accumulating evidence suggests that glial activation leading to the release of proinflammatory molecules acting on neurons is important in the complex syndrome of opioid dependence and withdrawal. This paper focuses on the recent advances in our understanding of the vital role that glia-neuron interactions play in opioid dependence and withdrawal within the PAG. We summarize those neurochemical mechanisms associated with opioid withdrawal including the recently defined importance of TNFα release from activated glial cells that communicate with TNF receptors on PAG neurons.

1. Introduction

Addiction to the illicit and prescribed use of opiate narcotics is a significant public health issue [1]. In the United States, an estimated 22.6 million Americans aged 12 or older were illicit drug users (Report from the 2012 National Survey on Drug Use and Health: National Findings. Substance Abuse and Mental Health Services Administration, Department of Health and Human Services). Addiction to opioids is a complex syndrome involving tolerance, drug-seeking, and physical dependence with withdrawal avoidance behaviors [2]. Physical withdrawal is a major cause of compulsive drug-taking behavior and short-term relapse [3, 4]. The severity of opioid dependence and the somatic symptoms triggered by withdrawal are major contributors to the addictive potential of opioid narcotics (Nestler EJ, Mount Sinai Medical Center, personal communication). Chronic opioid use in patients is further complicated by increased drug requirement for efficacy as well as hyperalgesia. Opioid withdrawal is believed to result from adaptations on multiple levels within the nervous system. Functional studies have implicated an important role for the periaqueductal gray (PAG) in the expression of many signs and symptoms of opioid withdrawal, but the cellular and molecular mechanisms are not fully understood. While opioid receptor-effector uncoupling has been implicated in physical dependence, this phenomenon cannot fully account for withdrawal signs and symptoms or rebound responses in neurons after the administration of opioid receptor antagonists [5]. Recently, the importance of glial activation and the release of proinflammatory cytokines within the PAG acting on neuronal receptor in withdrawal responses has been reported [6]. This topical report will review these recent findings and this emerging paradigm whereby these phenomena maybe mechanistically linked and better explain the complex syndrome of opioid dependence and withdrawal.

2. Opioid Withdrawal in Humans and Animal Model Systems

The term dependence will be used here in the context of the withdrawal syndrome that is characteristically observed upon the cessation of opioids after chronic use, or associated with the administration of opioid antagonists. In humans, the signs and symptoms of withdrawal include stomach cramps, diarrhea, rhinorrhea, sweating, elevated heart rate and increased blood pressure, irritability, dysphoria, hyperalgesia, and insomnia [7, 8]. After abrupt cessation of heroin or morphine use, the withdrawal syndrome develops within 24 hours and generally persists with declining severity for 1 week to 10 days. However, dysphoria and anhedonia can persist for much longer [8]. The withdrawal syndrome contributes to opioid addiction during cycles of opioid use or abuse presumably because repeated dosing is maintained or escalated to avoid the withdrawal syndrome leading to development of more profound tolerance and dependence [2, 8]. Furthermore, naloxone-precipitated withdrawal has been used to quantify opioid dependence in human volunteers [9, 10].

These signs and symptoms found in humans can be replicated in models of compulsive drug use in animals [8]. As such, animal models have very strong predictive validity with regard to human dependence for the same opioids [8]. For example, these signs are readily observed and quantified following administration of antagonists such as naloxone (termed “naloxone-precipitated withdrawal”) or after abrupt cessation of treatment with relatively short-acting opioids (termed “spontaneous withdrawal”) [8]. In rats and mice, sympathetic and parasympathetic imbalances associated with signs of opioid withdrawal include, but are not limited to, “wet-dog” shakes, jumps, burrowing, hyper-reactivity, abnormal posture, teeth chatter, piloerection, ptosis, lacrimation, rhinorrhea, diarrhea, abrupt weight loss, penile erection, and ejaculation [8, 11, 12]. In these models, the brain regions contributing to the physical signs of opiate withdrawal include the periaqueductal gray (PAG) area, the locus coeruleus, amygdala, ventral tegmental area, nucleus accumbens, hypothalamus, and spinal cord [13].

3. Anatomical Overview of the PAG: Afferents and Efferents

The PAG constitutes a cell-dense region, bordered laterally by the descending tectospinal fibers, which surrounds the midbrain aqueduct [14]. In the rostral midbrain (at the level of posterior commissure) as the third ventricle narrows to become the midbrain aqueduct, the PAG forms as an elongated, oval-shaped collection of neurons in continuity with the periventricular gray matter of the hypothalamus [14]. The functional studies provided a basis to subdivide the PAG into dorsal and ventrolateral longitudinal columns [14]. Both the ventrolateral PAG (vlPAG) and lateral PAG (lPAG) project extensively to ventromedial and ventrolateral medullary regions [14]. Distinct PAG columns project to specific hypothalamic and midline and intralaminar thalamic regions [15, 16]. The vlPAG receives afferents from the dorsal horn of the spinal cord and the nucleus of the solitary tract and projects to both the rostral and caudal ventrolateral medulla and the ventromedial medulla [14]. Amygdaloid projections to the PAG arise principally from the central nucleus and terminate in all but the dlPAG column. The lateral hypothalamic area projects selectively to the vlPAG [14]. Many of these nuclei are associated with withdrawal behaviors [17].

4. The Role of the PAG in Morphine Withdrawal

Functional studies have implicated a role for the PAG in the expression of many signs of opioid withdrawal, but the molecular mechanisms are not fully understood. The anatomical sites that mediate the diverse symptoms of physical opiate withdrawal have been explored using both intracerebral injections of opioid receptor antagonists and central nervous system lesions in dependent animals [11]. The PAG is rich in opioid receptors and endogenous opioid peptides and mediates physiological functions [17, 18]. Opioid antagonists microinjected into the PAG elicit strong withdrawal signs in rats implanted with pellets of morphine [11, 19]. Intraperitoneal naloxone precipitates morphine withdrawal signs in rats with chronic morphine infused into the PAG [20]. Endogenous peptide β-endorphin infused into the PAG for 72 h followed by naloxone elicits a typical morphine withdrawal-like syndrome [21]. The number of Fos immunoreactive neurons in the lateral and ventrolateral subdivisions of the PAG is increased after opioid withdrawal in both awake and anesthetized rats, which is most predominant in the caudal areas of the ventrolateral PAG [2224]. Electrophysiologic studies during opioid withdrawal on opioid-sensitive neurons in the PAG display enhanced activity caused by induction of a novel opioid-sensitive currents distinct from the potassium conductance modulated by acute exposure to opioids [25]. Withdrawal induced neuronal activation occurs in lateral and ventrolateral columns of neurons, and particularly the caudal ventrolateral PAG [23]. Taken together, the data suggest that the PAG performs a key role in the phenomena of morphine withdrawal.

5. Neurochemical Changes within the PAG Associated with Morphine Withdrawal

Many attempts have been made to investigate neuronal mechanisms involved in opioid dependence and withdrawal responses. A large range of neurochemical mechanisms have been identified in the neurons that may contribute to the opioid withdrawal syndrome, some of which are highlighted here.

5.1. Enkephalins and the Neuroanatomical Localization of Opioid Withdrawal

The PAG in the adult rodent brain contains a large number of opioid receptors and their naturally occurring peptide ligands [18] and is therefore very sensitive to the administration of opioid receptor antagonists and agonists [13]. Preproenkephalin (PPE) mRNA in the caudal periaqueductal gray (cPAG) is increased by either spontaneous morphine withdrawal or treatment with the opioid antagonist naloxone in rats [26]. In addition, the overexpression of PPE mRNA in the cPAG returned to the control levels after disappearance of morphine withdrawal signs [26]. Furthermore, increased expression of the neuronal transcription factor Fos, as a marker for neuronal activation, has been observed in the lateral, ventrolateral, and importantly, caudal vlPAG neurons during naloxone-precipitated withdrawal in rats chronically treated with morphine [23]. Fos and Jun reportedly regulate the expression of PPE mRNA [27]. Corroborating these findings, morphine withdrawal precipitates increased Fos-like immunoreactivity in the PAG [23]. These results suggest that increased Fos facilitates the synthesis of PPE mRNA during morphine withdrawal [28]. The selective anatomical localization of changes in PPE gene expression in the PAG associated with morphine withdrawal, rather than the striatum, caudate-putamen, or paraventricular-hypothalamic nucleus, is further evidence that the PAG is intimately and mechanistically linked with opioid withdrawal responses [26]. Furthermore, local administration of an enkephalin analog or peptidase inhibitors into the cPAG suppresses morphine withdrawal signs [12, 28]. Together, these findings suggest that enkephalinergic neurons in the PAG may play a critical role in the recovery phase of morphine withdrawal.

5.2. The Role of Adenylyl Cyclase in Opioid Withdrawal

Chronic opioid use is associated with a decoupling of opioid G-protein coupled receptors. Importantly, there remains much to be learned about how opioid receptors become decoupled with chronic opioid administration and how this relates to the pathophysiology of opioid withdrawal that may precipitate drug-seeking behaviors and perpetuate physical dependence. The mechanism appears to involve G-protein coupled receptor-induced activation of adenylyl cyclase via protein kinase A [30, 31]. Similarly, biochemical measures of rebound, such as increased neuronal adenylyl cyclase activity, have been widely reported during opioid withdrawal [32]. Although opioid agonists acutely inhibit adenylyl cyclase activity in the PAG [33], there is a compensatory increase in adenylyl cyclase signaling during chronic treatment with morphine resulting in rebound hyperactivity of this cascade during withdrawal [32]. The mechanism is suggested by Ingram et al., who showed that opioid dependence induces efficacious coupling of mu-receptors to presynaptic inhibition in GABAergic nerve terminals via adenylyl cyclase- and protein kinase A-dependent processes in the PAG [5]. Opioid withdrawal may therefore result in a loss of this coupling and neuronal hyperexcitation of opioid-sensitive PAG neurons [25, 34].

5.3. A Role for Protein Kinase A in Opioid Withdrawal

Protein kinase A (PKA) refers to a family of enzymes whose activity is dependent on cellular levels of cyclic AMP (cAMP). Chronic morphine treatment increases the level of adenylyl cyclase and cAMP-dependent PKA [35]. Downstream of PKA, the expression and phosphorylation of the cAMP-regulated transcription factor cAMP response element-binding protein (CREB) are selectively upregulated after chronic morphine treatment [35]. Additional evidence for an important role for PKA on opioid withdrawal was presented by Punch and colleague who demonstrated that intra-PAG infusion of a PKA inhibitor, Rp-cAMPS, attenuates withdrawal signs in morphine-dependent rats, while a PKA activator, Sp-cAMPS, induces withdrawal-like signs in morphine naïve rats [36]. Microinjections of PKA inhibitors 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine and H7 into the PAG attenuate a spectrum of opioid-withdrawal behaviors [37]. Electrophysiological and biochemical findings have suggested a role for the cAMP system in the chronic actions of opiates in PAG regions [38]. These data provide further direct evidence for the involvement of the cAMP-PKA system in the PAG in the pathophysiologic and complex behavioral manifestations of opiate withdrawal [36].

5.4. A Functional Role for PAG GABAergic Neurons in Opioid Withdrawal

Activation of a subpopulation of GABAergic neurons in the PAG also plays an important role in regulating opioid responses and withdrawal [39]. During opioid withdrawal in vitro, GABAergic neurons show hyperexcitability [25, 34] and increased release of GABA, but not glutamate, is observed in the PAG [5]. Hyperexcitation of GABAergic PAG neurons and the resulting increase in GABAergic inhibition of PAG output neurons toward targets in the hypothalamus and ventral medulla has been implicated in the initiation of PAG-mediated signs of opioid withdrawal [25, 40]. Bagley and colleagues found that hyperexcitation of PAG cell bodies is a result of increased GABA transporter 1 (GAT-1) currents via a PKA-dependent mechanism [34]. As noted, the upregulation of adenylyl cyclase and PKA signaling has consistently been associated with opioid withdrawal [40]. Importantly, this enhanced adenylyl cyclase signaling following chronic morphine treatment is associated with GABAergic terminal hyperexcitability during withdrawal, and this response is inhibited by a concomitant increase in endogenous adenosine in the PAG neurons [41]. GAT-1 currents could therefore contribute to the modulation of GABA release and initiation of opioid withdrawal. GAT-1 activity directly produces opioid withdrawal signs through direct hyperexcitation of GABAergic PAG neurons and nerve terminals, which presumably enhances GABAergic inhibition of PAG output neurons [42].

6. A Critical Role for Glial Activation in Morphine Withdrawal

Research on glial cells has come of age. Until a few years ago, glia cells were simply considered the glue that holds the neuronal cells together, but otherwise had no active role [43]. Abundant recent evidence confirms that glial cells are highly complex and engaged in a plethora of functions. The role of glia in, among other examples, synapse formation, synapse maturation, and plasticity and the rapid conduction of action potentials, as well as their immunological functions in the nervous system, have by now been unequivocally established [43]. Glial cells are generally distinguished in subclasses based on their diverse morphology and function. These include microglia, the immunocompetent and specialized brain macrophages; astrocytes, which represent the major glial component in the CNS and constitute up to 20–50% of the brain volume; NG2-glia, a peculiar type of glial cells that receive direct synaptic input from neurons; Schwann cells and oligodendrocytes form layers of myelin around neuronal axons in the peripheral and central nervous system, respectively [44, 45].

Nonetheless, our understanding of the role of glial cells in the complex syndrome of opioid dependence and withdrawal is still in its infancy. Glial cells, particularly astrocytes, envelop neuronal synapses and participate in the physiological control of synaptic transmission and plasticity via the release of synaptically effective mediators, a process called gliotransmission [29, 46, 47]. Evidence has now shown that glial cells may be critically involved in morphine dependence/withdrawal [6, 48, 49]. Morphine withdrawal induces glial activation and proinflammatory mediator expression in the different sites of the brain [50]. Chronic morphine treatment causes glial activation in the spinal cord, posterior cingulate cortex, hippocampus, and PAG [6, 51].

Chronic administration of systemic or intrathecal morphine activates spinal glia cells leading to an upregulation of proinflammatory cytokine release [52, 53]. Anti-inflammatory cytokines block the chronic morphine withdrawal-induced symptoms including pain at the spinal level [48, 52, 54]. AV411 is a blood-brain barrier permeable nonspecific phosphodiesterase inhibitor that is also known to suppress glial cell activation [49]. Systemic AV411 documents suppression of proinflammatory responses in vitro and in vivo [49]. Ledeboer and colleagues have demonstrated that coadministration of morphine with systemic AV411 suppresses morphine withdrawal and that AV411 also reduces systemic morphine-upregulated astrocytic and microglial activation markers in the brain and spinal cord [49, 55]. Coadministration of AV411 with morphine significantly reduces the naloxone precipitated opioid withdrawal behaviors across a 60 min postnaloxone time course [49, 55]. AV411 further downregulates morphine withdrawal-induced elevations of astrocytic GFAP and microglial CD11b activation markers, IL-1β, MCP-1, and MIP-3α in the PAG [50]. AV411 also prevents spontaneous morphine and oxycodone withdrawal-induced weight loss [50].

Although it was long assumed that opioid-induced neuroinflammation must be mediated via activation of classic opioid receptors, recent data contests this assumption [56, 57]. The series of multidisciplinary studies provided converging lines of evidence that morphine binds to an accessory protein of glial toll-like receptor 4 (TLR4), myeloid differentiation protein 2 (MD-2), thereby inducing TLR4 oligomerization and triggering proinflammation [58]. Direct activation of glial TLR4 induces overexpression of TNFα [59, 60]. TNFα is one of a handful of identified gliotransmitters [46, 61]. TLR4 inhibitor attenuated precipitated withdrawal in these morphine-dependent rats [62]. Our studies further demonstrate that morphine withdrawal induces astrocytic activation to release TNFα in the PAG and that, interestingly, exogenous TNFα injection into the PAG evokes morphine withdrawal-like behaviors [6].Thus, available evidence suggests TNFα plays a central role in the glial-neuronal interactions that influence drug abuse [29] by modulating synaptic transmission [47, 63].

7. Glia-Neuron Interactions Associated with Morphine Withdrawal in the PAG

In recent years, a considerable body of evidence has demonstrated the existence of reciprocal communication between the glial and neuronal cells, showing that the glial cells have an essential role in the regulation of the functional activity of the nervous system [64]. The glial cells release several substances that act as gliotransmitters and may influence glia-neuron communications as well as neuronal differentiation and plasticity [64]. At the neuronal interface, astrocytes exert a number of homeostatic functions that collectively contribute to maintain the microenvironment in conditions assuring optimal neuronal functions (for review see [45]). It has been estimated that the territory of each rodent astrocyte may contain 100,000 synapses and hundreds of dendrites [65, 66]. Astrocytes have privileged access to synapses. Because of the reciprocal signaling that can occur between astrocytes and synaptic terminals, these structures have been termed the “Tripartite Synapse” [67]. Astrocytes play a variety of roles in the regulation of synaptic transmission of neurons [29]. In addition to such supportive functions, astrocytes release chemical transmitters that modulate neuronal function [29]. Astrocytes respond to neuronal activity and neurotransmitters through the activation of neuronal receptors [68].

Further evidence suggests that glial cells are intimately involved in the active control of neuronal activity [67, 69]. Previous studies demonstrate a close interaction specifically between astrocytes and neurons treated with opioids [70]. Activation of astrocytes induces the synthesis and release of substances (e.g., cytokines, glutamates) capable of modulating the functions of surrounding cells, including neurons [71]. Proinflammatory mediators can exert direct actions on neurons [72] as well as induce various downstream changes that alter neuronal functions, potentially contributing to opioid withdrawal [73]. In particular, the increased release of CNS cytokines by activated glia may greatly influence or modulate neuronal functions [74, 75]. For example, TNFα increases the activity of glutamatergic AMPA receptors [76], and potentiates inward currents in neuronal tetrodotoxin-resistant sodium channels [77]. TNFα also increases spontaneous and evoked neurotransmitter release from presynaptic terminals in the hippocampus [78]. In addition, TNFα increases the neuronal cell surface expression of both neuronal AMPA and NMDA receptors [71, 79]. This pattern of changes is expected to create an overall increase in neuronal excitatory tone [71, 80]. Chronic adaptive molecular mechanisms involve gene expression and/or some protein kinases, which are relevant for signaling processes involving protein phosphorylation and gene expression [81]. In our recent studies, glial-neuronal interactions mediated through TNFα release by activated glial cells, altered neuronal mitogen-activated protein kinase (MAPK) and transcriptional factors in the PAG associated with morphine withdrawal [6].

On a subcellular level, the extracellular signal-regulated kinases (ERK1/2) is a family of serine/threonine protein kinases that have been functionally linked to addiction through phosphorylation of transcription factors leading to changes in target gene expression [81]. Recently, several studies have shown that the spinal ERK pathway contributes to naloxone-precipitated withdrawal in morphine-dependent rats [8285]. Our studies demonstrate that phosphorylation of ERK1/2 in the PAG is upregulated in the rats with morphine withdrawal. Phosphorylation of ERK is one of the major pathways for induction of Fos. Morphine withdrawal-induced increases in ERK activity results in an enhancement in Fos [85]. The strong induction of Fos expression in the PAG was found after naloxone injection to morphine-dependent rats [23]. Morphine withdrawal-induced overexpression of Fos has been colocalized with the phosphorylation of ERK in the vlPAG [6]. CREB has also been implicated in neural plasticity, including the changes that occur during stress and drug addiction [35, 86, 87]. Chronic morphine increases levels of CREB in the CNS [88, 89]. Chronic morphine dependence exerts long-lasting effects of morphine dependence on gene expression in different sites at the supraspinal level [90, 91]. We observe an increase in PAG neuronal CREB associated with morphine withdrawal rats [6].

Evidence shows that increased TNFα in states of inflammation, induces pERK phosphorylation in neurons [92], and that enhanced ERK signaling facilitates Fos expression in drug abuse [93]. CREB can be activated by kinases including ERK1/2 and PKA, which induce its transcriptional activity [94]. We have found that microinjection of recombinant TNFα into the vlPAG induces morphine withdrawal-like behavioral response and phosphorylation of ERK1/2 and CREB, and expression of Fos in the PAG [6]. Naloxone-precipitated morphine withdrawal induces upregulation of GFAP and TNFα in the PAG [6]. We inject HSV vector overexpressing p55TNF soluble receptor into the PAG in morphine withdrawal rats to prevent TNF from binding TNFR on the neurons and find that TNF soluble receptor mediated by HSV vectors suppresses morphine withdrawal behaviors and phosphorylation of neuronal ERK1/2 and transcription factors of neuronal CREB and Fos [6]. In addition, TNFα is colocalized with GFAP, but the TNF receptor colocalizes with NeuN, suggesting that TNFα is derived from astrocytes and TNF receptors are primarily on the surrounding neurons. Therefore, our studies demonstrate the importance of glial-neuronal interactions in morphine withdrawal within the PAG, suggesting that glial TNFα binds neuronal TNF receptors to induce phosphorylation of ERK1/2 and CREB, altering the expression of neuronal activation marker, Fos.

8. Summary

In summary, the activation of glial cells in the PAG in response to opioids and other stimuli including inflammation, ischemia, and invading pathogens can have a profound impact on the functioning of nearby neuronal cells. Importantly, recent data show that chronic opioid exposure induces glial activation and proinflammatory mediator expression in the PAG associated with the complex syndrome of opioid dependence and withdrawal. Specifically, increased TNFα on glial cells activated by opioids directly impacts PAG neuronal functioning including phosphorylation of ERK1/2 and CREB, alteration in neuronal gene expression, and the precipitation of withdrawal symptoms after naloxone or opioid discontinuation. Inhibiting the biofunctions of TNFα suppresses chronic morphine withdrawal and reverses the neurochemical response [48, 52, 54]. Therefore, we believe that the interactions of glial-neuronal interactions mediated by the interactions of PAG glial TNFα with neuronal TNFR may play an important role in complex syndrome of opioid withdrawal (Figure 1). Collectively, these findings lay the groundwork for future studies aimed at further integrating the observed glial molecules and changes of neuronal markers in the PAG. These findings also suggest that the inhibition of TNFα may represent a targeted new approach to preventing opioid withdrawal.

Conflict of Interests

The authors declare no conflict of interests.


This work was supported by NIHDA020078, NS066792, DA026734, and DA025527 (S.H.). The authors thank the kind support from Dr. David Fink and Dr. Marina Mata (Neurology, University of Michigan, MI).


  1. L. F. Chu, D. Y. Liang, X. Li et al., “From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics,” Pharmacogenetics and Genomics, vol. 19, no. 3, pp. 193–205, 2009. View at: Publisher Site | Google Scholar
  2. G. F. Koob and M. Le Moal, “Drug abuse: Hedonic homeostatic dysregulation,” Science, vol. 278, no. 5335, pp. 52–58, 1997. View at: Publisher Site | Google Scholar
  3. J. Cami and M. Farre, “Drug addiction,” The New England Journal of Medicine, vol. 349, pp. 975–986, 2003. View at: Publisher Site | Google Scholar
  4. A. Kvist, P. Fagergren, J. Whittard et al., “Dysregulated postsynaptic density and endocytic zone in the amygdala of human heroin and cocaine abusers,” Biological Psychiatry, vol. 69, no. 3, pp. 245–252, 2011. View at: Publisher Site | Google Scholar
  5. S. L. Ingram, C. W. Vaughan, E. E. Bagley, M. Connor, and M. J. Christie, “Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway,” Journal of Neuroscience, vol. 18, no. 24, pp. 10269–10276, 1998. View at: Google Scholar
  6. S. Hao, S. Liu, X. Zheng et al., “The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats,” Neuropsychopharmacology, vol. 36, no. 3, pp. 664–676, 2011. View at: Publisher Site | Google Scholar
  7. P. Cushman and V. P. Dole, “Detoxification of rehabilitated methadone maintained patients,” Journal of the American Medical Association, vol. 226, no. 7, pp. 747–752, 1973. View at: Publisher Site | Google Scholar
  8. M. M. Morgan and M. J. Christie, “Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human,” British Journal of Pharmacology, vol. 164, pp. 1322–1334, 2011. View at: Publisher Site | Google Scholar
  9. K. C. Kirby, M. L. Stitzer, and S. J. Heishman, “Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II,” Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 2, pp. 730–737, 1990. View at: Google Scholar
  10. K. L. Preston, G. E. Bigelow, and I. A. Liebson, “Effects of sublingually given naloxone in opioid-dependent human volunteers,” Drug and Alcohol Dependence, vol. 25, no. 1, pp. 27–34, 1990. View at: Publisher Site | Google Scholar
  11. E. Laschka, Teschemacher Hj., P. Mehraein, and A. Herz, “Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas,” Psychopharmacologia, vol. 46, no. 2, pp. 141–147, 1976. View at: Google Scholar
  12. G. F. Koob, R. Maldonado, and L. Stinus, “Neural substrates of opiate withdrawal,” Trends in Neurosciences, vol. 15, no. 5, pp. 186–191, 1992. View at: Publisher Site | Google Scholar
  13. A. A. McPhie and G. A. Barr, “Regional Fos expression induced by morphine withdrawal in the 7-day-old rat,” Developmental Psychobiology, vol. 51, no. 7, pp. 544–552, 2009. View at: Publisher Site | Google Scholar
  14. K. A. Keay and R. Bandler, “Periaqueductal Gray,” in The Rat Nervous System, G. Paxinos, Ed., pp. 243–257, Elsevier Academic Press, New York, NY, USA, 3rd edition, 2004. View at: Google Scholar
  15. N. S. Floyd, K. A. Keay, and R. Bandler, “A calbindin immunoreactive 'deep pain' recipient thalamic nucleus in the rat,” NeuroReport, vol. 7, no. 2, pp. 622–626, 1996. View at: Google Scholar
  16. K. E. Krout and A. D. Loewy, “Periaqueductal gray matter projections to midline and intralaminar thalamic nuclei of the rat,” The Journal of Comparative Neurology, vol. 424, pp. 111–141, 2000. View at: Publisher Site | Google Scholar
  17. R. Bandler and M. T. Shipley, “Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?” Trends in Neurosciences, vol. 17, no. 9, pp. 379–389, 1994. View at: Publisher Site | Google Scholar
  18. C. W. Vaughan and M. J. Christie, “Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductalgrey in vitro,” Journal of Physiology, vol. 498, no. 2, pp. 463–472, 1997. View at: Google Scholar
  19. R. Maldonado, L. Stinus, L. H. Gold, and G. F. Koob, “Role of different brain structures in the expression of the physical morphine withdrawal syndrome,” Journal of Pharmacology and Experimental Therapeutics, vol. 261, no. 2, pp. 669–677, 1992. View at: Google Scholar
  20. M. A. Bozarth, “Physical dependence produced by central morphine infusions: an anatomical mapping study,” Neuroscience and Biobehavioral Reviews, vol. 18, no. 3, pp. 373–383, 1994. View at: Publisher Site | Google Scholar
  21. E. Wei and H. Loh, “Physical dependence on opiate like peptides,” Science, vol. 193, no. 4259, pp. 1262–1263, 1976. View at: Google Scholar
  22. R. L. Stornetta, F. E. Norton, and P. G. Guyenet, “Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats,” Brain Research, vol. 624, no. 1-2, pp. 19–28, 1993. View at: Google Scholar
  23. B. Chieng, K. A. Keay, and M. J. Christie, “Increased fos-like immunoreactivity in the periaqueductal gray of anaesthetised rats during opiate withdrawal,” Neuroscience Letters, vol. 183, no. 1-2, pp. 79–82, 1995. View at: Publisher Site | Google Scholar
  24. P. Couceyro and J. Douglass, “Precipitated morphine withdrawal stimulates multiple activator protein-1 signaling pathways in rat brain,” Molecular Pharmacology, vol. 47, no. 1, pp. 29–39, 1995. View at: Google Scholar
  25. B. Chieng and M. J. Christie, “Local opioid withdrawal in rat single periaqueductal gray neurons in vitro,” Journal of Neuroscience, vol. 16, no. 22, pp. 7128–7136, 1996. View at: Google Scholar
  26. Y. Fukunaga and S. Kishioka, “Enkephalinergic neurons in the periaqueductal gray and morphine withdrawal,” Japanese Journal of Pharmacology, vol. 82, no. 3, pp. 175–180, 2000. View at: Publisher Site | Google Scholar
  27. J. L. Sonnenberg, F. J. Rauscher III, J. I. Morgan, and T. Curran, “Regulation of proenkephalin by Fos and Jun,” Science, vol. 246, no. 4937, pp. 1622–1625, 1989. View at: Google Scholar
  28. Y. Fukunaga, S. Nishida, N. Inoue, M. Miyamoto, S. Kishioka, and H. Yamamoto, “Time course of morphine withdrawal and preproenkephalin gene expression in the periaqueductal gray of rats,” Molecular Brain Research, vol. 55, no. 2, pp. 221–231, 1998. View at: Publisher Site | Google Scholar
  29. P. G. Haydon, J. Blendy, S. J. Moss, and F. Rob Jackson, “Astrocytic control of synaptic transmission and plasticity: a target for drugs of abuse?” Neuropharmacology, vol. 56, supplement 1, pp. 83–90, 2009. View at: Publisher Site | Google Scholar
  30. M. Guo, R. M. Pascual, S. Wang et al., “Cytokines regulate β-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA- and EP2 receptor-dependent mechanisms,” Biochemistry, vol. 44, no. 42, pp. 13771–13782, 2005. View at: Publisher Site | Google Scholar
  31. S. A. Shore, J. Laporte, I. P. Hall, E. Hardy, and R. A. Panettieri, “Effect of IL-1β on responses of cultured human airway smooth muscle cells to bronchodilator agonists,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 6, pp. 702–712, 1997. View at: Google Scholar
  32. R. Z. Terwilliger, D. Beitner-Johnson, K. A. Sevarino, S. M. Crain, and E. J. Nestler, “A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function,” Brain Research, vol. 548, no. 1-2, pp. 100–110, 1991. View at: Google Scholar
  33. J. P. Fedynyshyn and N. M. Lee, “μ type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to G-protein-mediated inhibition of adenylyl cyclase,” FEBS Letters, vol. 253, no. 1-2, pp. 23–27, 1989. View at: Publisher Site | Google Scholar
  34. E. E. Bagley, M. B. Gerke, C. W. Vaughan, S. P. Hack, and M. J. Christie, “GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal,” Neuron, vol. 45, no. 3, pp. 433–445, 2005. View at: Publisher Site | Google Scholar
  35. S. B. Lane-Ladd, J. Pineda, V. A. Boundy et al., “CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence,” Journal of Neuroscience, vol. 17, no. 20, pp. 7890–7901, 1997. View at: Google Scholar
  36. L. J. Punch, D. W. Self, E. J. Nestler, and J. R. Taylor, “Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray,” Journal of Neuroscience, vol. 17, no. 21, pp. 8520–8527, 1997. View at: Google Scholar
  37. R. Maldonado, O. Valverde, C. Garbay, and B. P. Roques, “Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 352, no. 5, pp. 565–575, 1995. View at: Google Scholar
  38. T. Jolas and G. K. Aghajanian, “Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro,” Brain Research, vol. 755, no. 2, pp. 229–245, 1997. View at: Publisher Site | Google Scholar
  39. J. Hacker, N. P. Pedersen, B. C. H. Chieng, K. A. Keay, and M. J. Christie, “Enhanced Fos expression in glutamic acid decarboxylase immunoreactive neurons of the mouse periaqueductal grey during opioid withdrawal,” Neuroscience, vol. 137, no. 4, pp. 1389–1396, 2006. View at: Publisher Site | Google Scholar
  40. J. T. Williams, M. J. Christie, and O. Manzoni, “Cellular and synaptic adaptations mediating opioid dependence,” Physiological Reviews, vol. 81, no. 1, pp. 299–343, 2001. View at: Google Scholar
  41. S. P. Hack, C. W. Vaughan, and M. J. Christie, “Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro,” Neuropharmacology, vol. 45, no. 5, pp. 575–584, 2003. View at: Publisher Site | Google Scholar
  42. E. E. Bagley, J. Hacker, V. I. Chefer et al., “Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors,” Nature Neuroscience, vol. 14, no. 12, pp. 1548–1554, 2011. View at: Publisher Site | Google Scholar
  43. P. Stern, “Glia. Glee for glia. Introduction,” Science, vol. 330, no. 6005, p. 773, 2010. View at: Google Scholar
  44. D. B. Tower and O. M. Young, “The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in cerebral cortices of various mammalian species from mouse to whale,” Journal of Neurochemistry, vol. 20, pp. 269–278, 1973. View at: Google Scholar
  45. D. Rossi and A. Volterra, “Astrocytic dysfunction: insights on the role in neurodegeneration,” Brain Research Bulletin, vol. 80, no. 4-5, pp. 224–232, 2009. View at: Publisher Site | Google Scholar
  46. M. M. Halassa, T. Fellin, and P. G. Haydon, “The tripartite synapse: roles for gliotransmission in health and disease,” Trends in Molecular Medicine, vol. 13, no. 2, pp. 54–63, 2007. View at: Publisher Site | Google Scholar
  47. J. S. Bains and S. H. R. Oliet, “Glia: they make your memories stick!,” Trends in Neurosciences, vol. 30, no. 8, pp. 417–424, 2007. View at: Publisher Site | Google Scholar
  48. M. R. Hutchinson, S. T. Bland, K. W. Johnson, K. C. Rice, S. F. Maier, and L. R. Watkins, “Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward,” TheScientificWorldJOURNAL, vol. 7, no. 2, pp. 98–111, 2007. View at: Google Scholar
  49. A. Ledeboer, M. R. Hutchinson, L. R. Watkins, and K. W. Johnson, “Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes,” Expert Opinion on Investigational Drugs, vol. 16, no. 7, pp. 935–950, 2007. View at: Publisher Site | Google Scholar
  50. M. R. Hutchinson, S. S. Lewis, B. D. Coats et al., “Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast),” Brain, Behavior, and Immunity, vol. 23, no. 2, pp. 240–250, 2009. View at: Publisher Site | Google Scholar
  51. P. Song and Z. Q. Zhao, “The involvement of glial cells in the development of morphine tolerance,” Neuroscience Research, vol. 39, no. 3, pp. 281–286, 2001. View at: Publisher Site | Google Scholar
  52. V. Raghavendra, M. D. Rutkowski, and J. A. Deleo, “The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats,” Journal of Neuroscience, vol. 22, no. 22, pp. 9980–9989, 2002. View at: Google Scholar
  53. I. N. Johnston, E. D. Milligan, J. Wieseler-Frank et al., “A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine,” Journal of Neuroscience, vol. 24, no. 33, pp. 7353–7365, 2004. View at: Publisher Site | Google Scholar
  54. V. Raghavendra, F. Y. Tanga, and J. A. DeLeo, “Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats,” Neuropsychopharmacology, vol. 29, no. 2, pp. 327–334, 2004. View at: Publisher Site | Google Scholar
  55. S. S. Lewis, M. R. Hutchinson, B. D. Coats et al., “AV411, a blood brain barrier permeable glial activation inhibitor, reduces morphine withdrawal behaviors in rats,” Proceedings of the Society for Neuroscience, pp. 765–762, 2006. View at: Google Scholar
  56. M. R. Hutchinson, S. S. Lewis, B. D. Coats et al., “Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences,” Neuroscience, vol. 167, no. 3, pp. 880–893, 2010. View at: Publisher Site | Google Scholar
  57. M. R. Hutchinson, L. C. Loram, Y. Zhang et al., “Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity,” Neuroscience, vol. 168, no. 2, pp. 551–563, 2010. View at: Publisher Site | Google Scholar
  58. X. Wang, L. C. Loram, K. Ramos et al., “Morphine activates neuroinflammation in a manner parallel to endotoxin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 16, pp. 6325–6330, 2012. View at: Publisher Site | Google Scholar
  59. O. Saito, C. I. Svensson, M. W. Buczynski et al., “Spinal glial TLR4-mediated nociception and production of prostaglandin E2 and TNF,” British Journal of Pharmacology, vol. 160, no. 7, pp. 1754–1764, 2010. View at: Publisher Site | Google Scholar
  60. I. Bettoni, F. Comelli, C. Rossini et al., “Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice,” GLIA, vol. 56, no. 12, pp. 1312–1319, 2008. View at: Publisher Site | Google Scholar
  61. A. Volterra and J. Meldolesi, “Astrocytes, from brain glue to communication elements: the revolution continues,” Nature Reviews Neuroscience, vol. 6, no. 8, pp. 626–640, 2005. View at: Publisher Site | Google Scholar
  62. M. R. Hutchinson, Y. Zhang, M. Shridhar et al., “Evidence that opioids may have toll-like receptor 4 and MD-2 effects,” Brain, Behavior, and Immunity, vol. 24, no. 1, pp. 83–95, 2010. View at: Publisher Site | Google Scholar
  63. M. Pickering, D. Cumiskey, and J. J. O'Connor, “Actions of TNF-α on glutamatergic synaptic transmission in the central nervous system,” Experimental Physiology, vol. 90, no. 5, pp. 663–670, 2005. View at: Publisher Site | Google Scholar
  64. L. M. Garcia-Segura, B. Lorenz, and L. L. DonCarlos, “The role of glia in the hypothalamus: implications for gonadal steroid feedback and reproductive neuroendocrine output,” Reproduction, vol. 135, no. 4, pp. 419–429, 2008. View at: Publisher Site | Google Scholar
  65. E. A. Bushong, M. E. Martone, Y. Z. Jones, and M. H. Ellisman, “Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains,” Journal of Neuroscience, vol. 22, no. 1, pp. 183–192, 2002. View at: Google Scholar
  66. M. M. Halassa, T. Fellin, H. Takano, J. H. Dong, and P. G. Haydon, “Synaptic islands defined by the territory of a single astrocyte,” Journal of Neuroscience, vol. 27, no. 24, pp. 6473–6477, 2007. View at: Publisher Site | Google Scholar
  67. A. Araque, V. Parpura, R. P. Sanzgiri, and P. G. Haydon, “Tripartite synapses: Glia, the unacknowledged partner,” Trends in Neurosciences, vol. 22, no. 5, pp. 208–215, 1999. View at: Publisher Site | Google Scholar
  68. M. M. Halassa and P. G. Haydon, “Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior,” Annual Review of Physiology, vol. 72, pp. 335–355, 2009. View at: Publisher Site | Google Scholar
  69. Q. S. Liu, Q. Xu, G. Arcuino, J. Kang, and M. Nedergaard, “Astrocyte-mediated activation of neuronal kainate receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3172–3177, 2004. View at: Publisher Site | Google Scholar
  70. M. Narita, M. Suzuki, N. Kuzumaki, M. Miyatake, and T. Suzuki, “Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine,” Annals of the New York Academy of Sciences, vol. 1141, pp. 96–104, 2008. View at: Publisher Site | Google Scholar
  71. L. R. Watkins, M. R. Hutchinson, E. D. Milligan, and S. F. Maier, “'Listening' and 'talking' to neurons: implications of immune activation for pain control and increasing the efficacy of opioids,” Brain Research Reviews, vol. 56, no. 1, pp. 148–169, 2007. View at: Publisher Site | Google Scholar
  72. R. X. Zhang, A. Li, B. Liu et al., “IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats,” Pain, vol. 135, no. 3, pp. 232–239, 2008. View at: Publisher Site | Google Scholar
  73. T. Nakagawa and M. Satoh, “Involvement of glial glutamate transporters in morphine dependence,” Annals of the New York Academy of Sciences, vol. 1025, pp. 383–388, 2004. View at: Publisher Site | Google Scholar
  74. D. Srinivasan, J. H. Yen, D. J. Joseph, and W. Friedman, “Cell type-specific interleukin-1β signaling in the CNS,” Journal of Neuroscience, vol. 24, no. 29, pp. 6482–6488, 2004. View at: Publisher Site | Google Scholar
  75. W. Guo, H. Wang, M. Watanabe et al., “Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain,” Journal of Neuroscience, vol. 27, no. 22, pp. 6006–6018, 2007. View at: Publisher Site | Google Scholar
  76. A. De, J. M. Krueger, and S. M. Simasko, “Tumor necrosis factor α increases cytosolic calcium responses to AMPA and KCl in primary cultures of rat hippocampal neurons,” Brain Research, vol. 981, no. 1-2, pp. 133–142, 2003. View at: Publisher Site | Google Scholar
  77. X. Jin and R. W. Gereau, “Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-α,” Journal of Neuroscience, vol. 26, no. 1, pp. 246–255, 2006. View at: Publisher Site | Google Scholar
  78. F. Grassi, A. M. Mileo, L. Monaco, A. Punturieri, A. Santoni, and F. Eusebi, “TNF-α increases the frequency of spontaneous miniature synaptic currents in cultured rat hippocampal neurons,” Brain Research, vol. 659, no. 1-2, pp. 226–230, 1994. View at: Google Scholar
  79. L. Zhang, T. Berta, Z. Z. Xu, T. Liu, J. Y. Park, and R. R. Ji, “TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2,” Pain, vol. 152, no. 2, pp. 419–427, 2011. View at: Publisher Site | Google Scholar
  80. D. Stellwagen, E. C. Beattie, J. Y. Seo, and R. C. Malenka, “Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-α,” Journal of Neuroscience, vol. 25, no. 12, pp. 3219–3228, 2005. View at: Publisher Site | Google Scholar
  81. J. G. Liu and K. J. S. Anand, “Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence,” Brain Research Reviews, vol. 38, no. 1-2, pp. 1–19, 2001. View at: Publisher Site | Google Scholar
  82. X. Ren, Y. Noda, T. Mamiya, T. Nagai, and T. Nabeshima, “A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase,” Behavioural Brain Research, vol. 152, no. 2, pp. 243–250, 2004. View at: Publisher Site | Google Scholar
  83. J. L. Cao, J. H. He, H. L. Ding, and Y. M. Zeng, “Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent rats,” Pain, vol. 118, no. 3, pp. 336–349, 2005. View at: Publisher Site | Google Scholar
  84. D. L. Muller and E. M. Unterwald, “In vivo regulation of extracellular signal-regulated protein kinase (ERK) and protein kinase B (Akt) phosphorylation by acute and chronic morphine,” Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 2, pp. 774–782, 2004. View at: Publisher Site | Google Scholar
  85. C. Núñez, M. T. Castells, M. L. Laorden, and M. V. Milanés, “Regulation of extracellular signal-regulated kinases (ERKs) by naloxone-induced morphine withdrawal in the brain stress system,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 378, no. 4, pp. 407–420, 2008. View at: Publisher Site | Google Scholar
  86. E. J. Nestler, “Molecular neurobiology of addiction,” American Journal on Addictions, vol. 10, no. 3, pp. 201–217, 2001. View at: Publisher Site | Google Scholar
  87. R. Maldonado, J. A. Blendy, E. Tzavara et al., “Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB,” Science, vol. 273, no. 5275, pp. 657–659, 1996. View at: Google Scholar
  88. K. L. Widnell, D. S. Russell, and E. J. Nestler, “Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 10947–10951, 1994. View at: Publisher Site | Google Scholar
  89. T. Z. Shaw-Lutchman, M. Barrot, T. Wallace et al., “Regional and cellular mapping of camp response element-mediated transcription during naltrexone-precipitated morphine withdrawal,” Journal of Neuroscience, vol. 22, no. 9, pp. 3663–3672, 2002. View at: Google Scholar
  90. J. A. Blendy and R. Maldonado, “Genetic analysis of drug addiction: the role of cAMP response element binding protein,” Journal of Molecular Medicine, vol. 76, no. 2, pp. 104–110, 1998. View at: Publisher Site | Google Scholar
  91. E. J. Nestler, “Is there a common molecular pathway for addiction?” Nature Neuroscience, vol. 8, no. 11, pp. 1445–1449, 2005. View at: Publisher Site | Google Scholar
  92. I. C. Anthony, J. C. Arango, B. Stephens, P. Simmonds, and J. E. Bell, “The effects of illicit drugs on the HIV infected brain,” Frontiers in Bioscience, vol. 13, no. 4, pp. 1294–1307, 2008. View at: Publisher Site | Google Scholar
  93. S. M. Ferguson, S. Fasano, P. Yang, R. Brambilla, and T. E. Robinson, “Knockout of ERK1 enhances cocaine-evoked immediate early gene expression and behavioral plasticity,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2660–2668, 2006. View at: Publisher Site | Google Scholar
  94. M. Johannessen, M. P. Delghandi, and U. Moens, “What turns CREB on?” Cellular Signalling, vol. 16, no. 11, pp. 1211–1227, 2004. View at: Publisher Site | Google Scholar

Copyright © 2012 Handong Ouyang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

10389 Views | 1330 Downloads | 7 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.